Compare Ascendis Pharma A/S (ASND) vs Figs Inc (FIGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Figs Inc — how do they compare? Ascendis Pharma A/S trades at $263 (market cap $17.74B), while Figs Inc trades at $10.16 (market cap $1.68B). The key difference: Ascendis Pharma A/S is far larger — about 10.6× Figs Inc's market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, Figs Inc nearer its low. Which is the better fit depends on your goals.
| ASND | FIGS | |
|---|---|---|
Market Cap | $17.74B | $1.68B |
Sector | Health | Consumer Cyclical |
52-Week High | $277.18 | $17.12 |
52-Week Low | $163.32 | $5.81 |
Enterprise Value | $18.11B | $1.46B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
FIGS trades at $10.04, down 2.81% today, with a bearish technical signal from moving averages despite recent earnings beats. Revenue grew to $631.10M in 2025 with a 66.61% gross margin, but net cash flow remains negative. Analyst consensus is Buy with a $18.00 price target, suggesting significant upside from current levels.
The stock offers growth potential through healthcare apparel demand and global expansion, but faces risks from valuation multiples (P/E 45.64), margin pressures, and persistent negative cash flow. Investor sentiment is mixed amid cost headwinds and competitive dynamics in the apparel sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Figs Inc
FIGS Inc is a healthcare apparel company. It offers more fitted scrubs for men and women made of its proprietary fabric FIONx, which provides four-way stretch and has anti-odor, anti-wrinkle, and moisture-wicking properties.
Read more on FIGS →
